Is it always unethical to use a placebo in a clinical trial?

PLoS Medicine

Volumn 2, Issue 3, 2005, Pages 0177-0180

  Stang, Andreas ^a   Hense, Hans Werner ^b   Jöckel, Karl Heinz ^c   Turner, Erick H ^d,e,f   Tramèr, Martin R ^g  

^a MARTIN LUTHER UNIVERSITY HALLE WITTENBERG   (Germany)

^b UNIVERSITY OF MÜNSTER   (Germany)

^c UNIVERSITY HOSPITAL ESSEN   (Germany)

^d Portland Veterans Affair Medical Center   (United States)

^e OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^f OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^g GENEVA UNIVERSITY HOSPITALS   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

ANALGESIC AGENT; ANTIANGINA PECTORIS AGENT; ANTIASTHMATIC AGENT; ANTIDEPRESSANT AGENT; ANTIEMETIC AGENT; ANTIHISTAMINIC AGENT; ANTIHYPERTENSIVE AGENT; ANXIOLYTIC AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; GASTROINTESTINAL AGENT; HYPNOTIC AGENT; NAPROXEN; NONSTEROID ANTIINFLAMMATORY AGENT; ONDANSETRON; PLACEBO; PSYCHOTROPIC AGENT; ROFECOXIB;

CARDIOVASCULAR RISK; CLINICAL TRIAL; DRUG APPROVAL; DRUG EFFECT; DRUG EFFICACY; DRUG INDICATION; DRUG INDUSTRY; DRUG RESEARCH; DRUG SENSITIVITY; ETHICS; EVIDENCE BASED MEDICINE; HEADACHE; HEART DEATH; HEART INFARCTION; HUMAN; META ANALYSIS; METHODOLOGY; PAIN; PSYCHOSOMATICS; REVIEW; ARTICLE; MEDICAL ETHICS; RANDOMIZED CONTROLLED TRIAL (TOPIC);

ETHICS, MEDICAL; HUMANS; PLACEBOS; RANDOMIZED CONTROLLED TRIALS AS TOPIC;

EID: 18244365812     PISSN: 15491277     EISSN: 15491676     Source Type: Journal    
DOI: 10.1371/journal.pmed.0020072     Document Type: Review

References (20)

1. World Medical Association (2004 October) World Medical Association declaration of Helsinki: Ethical principles for medical research involving human subjects. Available: http://www.wma.net/e/policy/b3.htm. Accessed 3 February 2005.
2. Rothman KJ, Michels KB, Baum M (2000) Declaration of Helsinki should be strengthened. BMJ 321: 442-444.
3. Atkins D, Best D, Briss PA, Eccles M, and Falck-Ytter, et al. (2004) Grading quality of evidence and strength of recommendations. BMJ 328: 1490-1498.
4. Temple R, Ellenberg SS (2000) Placebo-controlled trials and active-control trials in the evaluation of new treatments. Part 1: Ethical and scientific issues. Ann Intern Med 133: 455-463.
5. Tramèr MR, Reynolds DJ, Moore RA, McQuay HJ (1998) When placebo controlled trials are essential and equivalence trials are inadequate. BMJ 317: 875-880.
6. Montori VM, Smieja M, Guyatt GH (2000) Publication bias: A brief review for clinicians. Mayo Clin Proc 75: 1284-1288.
7. Khan A, Khan SR, Walens G, Kolts R, Giller EL (2003) Frequency of positive studies among fixed and flexible dose antidepressant clinical trials: An analysis of the Food and Drug Administration summary basis of approval reports. Neuropsychopharmacology 28: 552-557.
8. Snapinn SM (2000) Noninferiority trials. Curr Control Trials Cardiovasc Med 1: 19-21.
9. Pasquina P, Tramèr MR, Walder B (2003) Prophylactic respiratory physiotherapy after cardiac surgery: Systematic review. BMJ 327: 1379-1381.
10. (2000) The American Heritage dictionary of the English language, 4th ed, 2003 version. Boston: Houghton Mifflin. 2,074 p.
11. Hume D (1739) A treatise of human nature, revised ed Selby-Bigge LA, editor. Oxford: Clarendon Press. 417 p.
12. Popper KR (1959) The logic of scientific discovery. London: Routledge. 479 p.
13. Rennie D (2004) Trial registration: A great idea switches from ignored to irresistible. JAMA 292: 1359-1362.
14. Turner EH (2004) A taxpayer-funded clinical trials registry and results database. PLoS Med 1: e60.
15. Andersen HC (2004) The emperor's new clothes. Mindfully.org. Available: http://www.mindfully.org/Reform/Emperors-New-Clothes.htm. Accessed 4 February 2005.
16. Bombardier C, Laine L, Reicin A, Shapiro D, Burgos-Vargas, et al. (2000) Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. VIGOR Study Group. N Engl J Med 343: 1520-1528.
17. Konstam MA, Weir MR, Reicin A, Shapiro D, Sperling RS, et al. (2001) Cardiovascular thrombotic events in controlled, clinical trials of rofecoxib. Circulation 104: 2280-2288.
18. Topol EJ (2004) Failing the public health - Rofecoxib, Merck, and the FDA. N Engl J Med 351: 1707-1709.
19. Merck (2004 September 30) Merck announces voluntary worldwide withdrawal of VIOXX. Available: http://www.vioxx.com/vioxx/documents/english/ vioxx_press_release.pdf. Accessed 27 December 2004.
20. Graham DJ (2004) Testimony of David J. Graham, MD, MPH, November 19, 2004. Washington (DC): United States Senate Committee on Finance. Available: http://www.finance.senate.gov/hearings/testimony/2004test/111804dgtest.pdf. Accessed 4 February 2005.